IGM today announced the appointment of Chris H. Takimoto, M.D., Ph.D., F.A.C.P., to the role of Chief Medical Officer, effective today. Dr. Takimoto will be responsible for global development of IGM's clinical pipeline of proprietary IgM antibodies.
National Jewish Health continues to increase its testing capabilities for COVID-19 antibodies, including the addition of new validated testing equipment.